Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review

Erlotinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations. The response rate to erlotinib is ~...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2018-07, Vol.9 (1), p.92-95
Main Authors: Ansari, Jawaher, Batubara, Enas, Ali, Muhammad, Farrag, Ashraf, Bashir, Farhat, Farghaly, Hussein R, Ali, Arwa M, Shaukat, Arif
Format: Article
Language:English
Subjects:
Cancer therapies
Care and treatment
Case reports
Chemotherapy
Complications and side effects
Development and progression
Disease
Drug therapy
Erlotinib
Family medical history
Inhibitor drugs
Interstitial lung diseases
Lung cancer
Medical imaging
Metastasis
Multivariate analysis
Mutation
Non-small cell lung cancer
Oncology
Patients
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Erlotinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations. The response rate to erlotinib is ~60% and the incidence of erlotinib-induced interstitial lung disease (ILD) is ~1-4%. The Response Evaluation Criteria in Solid Tumours (RECIST) tool is commonly used to assess response to erlotinib; however, evaluation of response and subsequent progression in the presence of atypical cystic lung changes may be challenging. We herein present a rare case of diffuse cystic lung changes secondary to erlotinib treatment in a patient with EGFR mutation-positive metastatic NSCLC. Challenges in assessing atypical tumour response to erlotinib, pitfalls in using RECIST and differential diagnosis of TKI-related ILD are discussed in detail.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2018.1620